Exploring the role of immunotherapy-based treatments for advanced non-small cell lung cancer with novel driver alterations

[1]  E. Felip,et al.  RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion. , 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Yongchang Zhang,et al.  Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer , 2022, Cell death & disease.

[3]  Yan Xu,et al.  Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients. , 2022, Clinical lung cancer.

[4]  S. Schokrpur,et al.  The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study , 2022, JTO clinical and research reports.

[5]  M. Meyerson,et al.  Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D mutated non-small cell lung cancer. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  X. Ji,et al.  Deciphering the tumor cell-infiltrating landscapes reveal microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC. , 2022, JCI insight.

[7]  M. Socinski,et al.  IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  Junyun Wang,et al.  Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma , 2021, Frontiers in Oncology.

[9]  Joe Y. Chang,et al.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[11]  M. Tsao,et al.  Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. , 2021, Clinical lung cancer.

[12]  Fanrong Zhang,et al.  Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions , 2020, Thoracic cancer.

[13]  J. Gainor,et al.  Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer , 2020, Cancer journal.

[14]  G. Argenziano,et al.  Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations , 2020, Therapeutic advances in medical oncology.

[15]  M. Ladanyi,et al.  Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  P. Fournel,et al.  Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  Young A Kim,et al.  MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function , 2019, International journal of molecular sciences.

[18]  A. Drilon,et al.  Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  M. Ladanyi,et al.  Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers , 2019, JCO precision oncology.

[20]  D. Galetta,et al.  BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  K. Takayama,et al.  Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer , 2019, Cancer medicine.

[22]  Yi-long Wu,et al.  Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. , 2018, Lung cancer.

[23]  A. Drilon,et al.  PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  A. Allen,et al.  Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi). , 2018, Lung cancer.

[25]  M. Mishaeli,et al.  BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check‐Point Inhibitors , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  J. Horton,et al.  A Phase II Study of Pembrolizumab in EGFR‐Mutant, PD‐L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  J. Landsberg,et al.  Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c‐MET Limit Cancer Immunotherapy , 2017, Immunity.

[28]  V. Gebski,et al.  Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[30]  S. Digumarthy,et al.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.

[31]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[32]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[33]  Toshikazu Nakamura,et al.  Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells , 2010, Proceedings of the National Academy of Sciences.

[34]  S. Ferrari,et al.  Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. , 2006, Blood.